Hyde Park
Hyde Park
Hyde Park, New York, United States6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06052267 | |
| ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Embolism and Thrombosis, Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, X-linked disease, anemia, blood coagulation disease, blood platelet disease, cardiovascular disorder, coagulation protein disease, connective tissue disorder, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hemophilia A, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, inherited hemoglobinopathy, sickle cell disease, thalassemia, thrombophilia, thrombotic disease, vascular disorder, vascular hemostatic disease, von Willebrand disease (hereditary or acquired) | Recruiting | Not stated | 2026-08-17 | NCT04398628 | |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-08-07 | NCT06739122 | |
| Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Pneumococcal Immunization | Active, not recruiting | Phase 3 | 2026-04-13 | NCT06824194 | |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | C3 glomerulonephritis, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, complement 3 glomerulopathy, glomerulonephritis, immune system disorder, kidney disorder, membranoproliferative glomerulonephritis, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-04-02 | NCT05809531 | |
| Access Cannulation Trial II | Dialysis; Complications; Vascular Access Complication | Recruiting | Not applicable | 2025-10-29 | NCT05490225 |